



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, 12th February, 2021.

To
The General Manager,
Listing Department,
BSE Limited,
1st Floor, New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street Fort,
Mumbai-400001.

Dear Sir/Ma'am,

Sub: Financial Results for the quarter ended 31st December, 2020 – Regulation 33 (3) (a).


Ref: Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Friday, 12th February, 2021 at 4.30 P.M. at the Corporate office of the Company, inter alia, considered and approved the unaudited Financial Results for the quarter ended 31st December, 2020.

Copy of un-audited Financial Results for the quarter ended 31st December, 2020 and Limited review Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,
for Vista Pharmaceuticals Limited



Akash Bhagadia
Company Secretary



Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. 85, Shivbagh, Ameerpet, Hyderabad - 16. Telangana

India Tel : 040-23741585

e-mail : admin.hyd@vistapharmaceuticals.com ● www.vistapharmaceuticals.com

Statement of Unaudited Financial Results for the Quarter ended 31st December,2020

(in Rs Lakhs)

S.No	Particulars	Quarter ended			Year to Date Nine Months ended on		Financial Year ended
		3 Months Ended	Preceding 3 Months Ended	Corresponding 3 Months ended in the Previous Year	Year To Date figures for the current Period ended	Year To Date figures for the Previous Period ended	Previous Year Ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
1	Income	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
	a. Revenue from operations	38.19	40.85	672.90	79.04	2194.73	2275.90
	b. Other income	15.01	8.28	3.54	23.38	335.12	374.77
2	Total Income (a+b)	53.19	49.14	676.44	102.42	2529.85	2650.68
3	Expenses						
	a) Cost of Material Consumed	24.92	37.49	558.19	62.41	1886.06	2289.54
	b) Change in Inventories	0.00	-	0.00	0.00	104.16	104.16
	c) Employee benefits expense	32.96	38.12	38.07	71.08	110.67	148.50
	d) Finance costs	23.79	36.50	33.71	121.43	118.97	154.02
	e) Depreciation and amortization expense	18.58	18.62	34.17	54.22	100.69	134.63
	f) Other expenses	18.56	21.80	6.74	52.10	181.22	213.43
	Total Expenses	118.80	152.53	670.88	361.24	2,501.77	3,044.29
4	Profit before tax (2-3)	-65.61	-103.39	5.56	-258.82	28.08	-393.61
5	Tax expense						
	(1) Current tax	0.00	0.00	1.07	0.00	5.40	0.00
	(2) Deferred tax	-17.36	(139.46)	25.71	-100.52	28.52	25.89
6	Net Profit for the Period (4-5)	(48.25)	36.06	(21.22)	(158.30)	(5.85)	(367.72)
7	Other comprehensive income (OCI)						
	(a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive income	-	-	-	-	-	-
8	Total Comprehensive income (6+7)	(48.25)	36.06	(21.22)	(158.30)	(5.85)	(367.72)
9	Paid-up equity share capital(Face Value of Rs.2/- each)	735.88	735.88	607.31	735.88	607.31	607.31
10	Other equity						2356.89
11	Earnings per equity share (Face value of Rs.10/- each)						
	(1) Basic	-0.13	0.11	-0.07	-0.44	-0.02	-1.22
	(2) Diluted	-0.13	0.11	-0.07	-0.44	-0.02	-1.22

Notes:

- The above Financial results as recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 12.02.2021.
- The Standalone Financial results for the quarter and nine months ended 31.12.2019 are reviewed by the Statutory Auditors of the Company as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND-AS 108 is not made.

(Signature)

VISTA PHARMACEUTICALS LIMITED

Registered Office : Gopalaipalli(Village),Narketpalli(Mandal),Nalgonda Dist.T.S. - 508254
(CIN: L24239TG1991PLC012264)

STANDALONE BALANCE SHEET AS AT 31st December, 2020

(Rs.in Lakhs)


Particulars	Note No.	2021	2020
ASSETS			
Non-current assets			
Property plant and Equipment	2.1	1056.59	1110.83
Capital Work In progress		898.24	878.20
Intangible assets	2.2	955.30	955.30
Financial assets			
Investments	2.3	3.05	1.71
Other financial assets	2.4	9.65	9.65
Deferred tax Asset (net)	2.12	1.26	37.97
Other non current assets	2.5	0.00	0.00
		2924.09	2993.66
Current assets			
Inventories	2.6	968.15	968.15
Financial assets			
Trade receivables	2.7	1079.96	1028.04
Cash and cash equivalent	2.8	22.43	22.52
Other financial assets	2.4	0.00	0.00
Other current assets	2.5	90.47	99.80
		2161.02	2118.52
		5085.12	5112.18
EQUITY AND LIABILITIES			
Equity			
Equity Share Capital	2.9	735.88	607.31
Other Equity	2.10	2828.71	2356.89
		3564.59	2964.20
Liabilities			
Non-current liabilities			
Financial Liabilities			
Borrowings	2.11	495.88	550.65
Deferred tax liabilities (net)		-	-
Other Non-Current liabilities		5.15	5.15
		501.03	555.80
Current liabilities			
Financial Liabilities			
Borrowings	2.11	655.15	996.07
Trade payables	2.13	293.01	516.15
Other financial liabilities	2.14	5.30	5.30
Liabilities for current tax (net)			
Provisions	2.15	28.25	23.62
Other current liabilities	2.16	37.80	51.05
		1019.50	1592.18
		5085.12	5112.17
TOTAL			

The accompanying Significant accounting policies and notes form an integral part of the Standalone financial

As per our report of even date
For A M Reddy & D R Reddy
Chartered Accountants
FRNo:009068S

D Ramakrishna Reddy
Partner
M.No.209211

Place: Hyderabad
Date:12.02.2021



For and on behalf of Board

A Reddy
Yerrabommanahalli Divakar Reddy
Director
(DIN:08574891)

VISTA PHARMACEUTICALS LIMITED

Registered Office : Gopalaipalli(Village),Narketpalli(Mandal),Nalgonda Dist.T.S. - 508254
(CIN: L24239TG1991PLC012264)

STANDALONE PROFIT & LOSS STATEMENT FOR THE YEAR ENDED 31st December, 2020

	Particulars	2021	2020
Income			
Revenue from operations	2.17	79.04	2275.90
Other income	2.18	20.09	374.77
Total Revenue		99.13	2650.68
Expenses			
Cost of materials consumed	2.19	13.87	2289.54
Changes in inventories	2.20	0.00	104.16
Employee benefits expense	2.21	71.08	148.50
Finance costs	2.22	121.19	154.02
Depreciation and amortization expense	2.1	54.22	134.635
Other expenses	2.23	100.64	213.43
Total Expenses		360.99	3044.29
Profit before tax		(261.87)	(393.61)
Tax expense			
(1) Current tax		0.00	0.00
(2) Deferred tax		0.00	25.89
Profit for the year		(261.87)	(367.72)
Other comprehensive income (OCI)			
Items that will not be reclassified to profit or loss		0.00	0.00
Tax on items that will not be reclassified to profit or loss		0.00	0.00
		0.00	0.00
Items that will be reclassified to profit or loss:			
loss			
Items that may be reclassified subsequently to profit or loss			
Total other comprehensive income/(loss) for the year, net of tax		0.00	0.00
Total comprehensive income for the year		(261.87)	(367.72)
Earnings per share:			
Basic earnings per share of 2/-each		(0.87)	(1.22)
Diluted earnings per share of 2/- each		(0.87)	(1.22)

The accompanying Significant accounting policies and notes form an integral part of the Standalone financial statements.

As per our report of even date
For A M Reddy & D R Reddy
Chartered Accountants
FRNo:009068S



For and on behalf of Board

(Signature)
Yerrabommanahalli Divakar Reddy
Director
(DIN:08574891)

D Ramakrishna Reddy
Partner
M.No.209211

Place: Hyderabad
Date:12.02.2021



A.M. REDDY & D.R. REDDY

CHARTERED ACCOUNTANTS

Annex 1 - Exhibit C1: Limited Review Report for listed entities other than banks and insurance companies - unaudited standalone quarterly results

Review report to Board of Directors of **VISTA PHARMACEUTICALS LIMITED.**

We have reviewed the accompanying statement of unaudited financial results of Vista Pharmaceuticals Limited for the Quarter and Nine Months ended 31st December 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our Conclusion is not modified in respect of this matter.

For M/s. AM Reddy & D R Reddy

Chartered Accountants

FRNo: 0090688


D Ramakrishna Reddy
Partner

M.No:209211

UDIN: 21209211AAAAAZ4205

Place of signature: Hyderabad

Date: 12-02-2021